PCN24 DEFINING GUIDELINES ON BRCA MUTATION TESTING AT A MEDICAL ONCOLOGY UNIT-AT AN UNIVERSITY HOSPITAL IN SOUTH-EASTERN BRAZIL
The risk cut off to recommend BRCA 1 and 2 gene testing varies from 10% for the American Society of Clinical Oncology to 20% in European countries. Considering pts with a previous diagnosis of breast cancer, we aimed to establish a risk cut off policy for genetic testing at our service, in terms of direct costs. A total of 130 pts with a previous breast cancer, in routine follow-up, received invitation to schedule consultation in the hereditary breast cancer unit. METHODS: Of these, 77 patients, were interviewed by a multidisciplinary team, and had their risk assessed based on family pedigree and confirmed pathological information (Frank Ts et al, JCO 20:1480 -1490 , 2002 . Direct costs of genetic testing were considered as the sum of costs of reagents, permanent equipment and personnel excluded. Prices in reais were converted to dolar (2.3 reais per dolar). RESULTS: Our survey have shown that 3 women in 77 surveyed were to be tested with a risk cut off established in 20% as compared to 16 with a risk assessment of >10%. Considering the offspring, screening those women would benefit 162 and 21other women, respectively, at 10% and 20% cut off. The total direct costs of gene testing would be $31,023.86 at 10% and $5816.97 at 20%. In case we consider all first degree women relatives as beneficiaries, independent of the result being positive or negative for BRCA mutation, cost effectiveness (CE) ratio of $191.50 per individual benefited at 10% and $276.99/beneficiary at 20%. CONCLUSION: A 20% cut off for genetic testing in this population with breast cancer seems very strict, since the number of women indicated for genetic testing was far bellow the 5% expected in breast cancer population. Considering the other family members, the higher cost associated with 10% cut off could benefit more women. To better understand the real-world dosing patterns of epoetin alfa (EPO) and darbepoetin alfa (DARB) in patients with cancer receiving chemotherapy, a large retrospective, observational study was undertaken to analyze dosing patterns and associated costs of patients treated with EPO and DARB in the outpatient setting. METHODS: Adult patients who had cancer and were receiving chemotherapy, had ≥2 EPO or DARB claims, and were newly initiated on erythropoiesis stimulating therapy (EST) between April 2003 and February 2005 were identified from a nationwide sample of outpatient medical claims from hospital clinics and office practices. EPO and DARB use was identified via HCPCS codes in medical claims with dose calculated using billed units. Average treatment duration, dosing frequency, mean cumulative dose, and total EST costs (using 2005 wholesale acquisition prices) were studied. RESULTS: A total of 1405 EPO and 1087 DARB patients met the inclusion criteria. Mean age (years; EPO 63 ± 13; DARB 62 ± 12) was similar between groups, with more women in the DARB group (EPO 62%; DARB 71%, p < 0.05). Weekly and extended dosing (≥Q2W) frequencies were utilized in patients receiving EPO (QW: 65%, Q2W: 29%, ≥Q3W: 6%) and DARB (QW: 11%, Q2W: 61%, ≥Q3W: 28%). Mean treatment duration was 54 ± 51 days for EPO and 52 ± 46 days for DARB. Mean cumulative dose for EPO and DARB was 296,070 IU and 1022 mcg corresponding to a dose only ratio of 290 : 1 (units EPO: mcg DARB) and total EST costs of $3603 and $4456, respectively. CON-CLUSION: In this large observational study, DARB treatment costs were substantially higher (24%) than EPO treatment costs. In addition, extended EPO and DARB dosing was common among patients with cancer receiving chemotherapy. McMaster University, Hamilton, ON, Canada, 2 Harvard University, Boston, MA, USA OBJECTIVES: To assess inter-rater agreement for Health Utilities Index (HUI) Mark 3 (HUI3) measurements of patients during treatment of acute lymphoblastic leukemia (ALL) in childhood. METHODS: Patients were age five years or older at time of study and enrolled in Dana Farber Cancer Institute 95-001 clinical trial. Parents-of-patients and clinicians, blinded to each other, completed self-administered HUI questionnaires at four assessment points during treatment: Induction of remission, CNS prophylaxis, intensification, and maintenance. Agreement between parents and clinicians, for HUI3 single-attribute and overall health-related quality of life (HRQL) utility scores, was assessed using a single-measure two-way mixed model intra-class correlation coefficient (ICC) and paired t-test. Mean differences in single-attribute and HRQL scores >0.05 and >0.03, respectively, are clinically important. Statistical significance was set at p < 0.05. ICC results were interpreted as follows: >0.50 strong agreement; 0.35-0.50 moderate agreement; 0.20-0.34 weak agreement; 0.00-0.19 negligible agreement. RESULTS: There were 375 patients who were surveyed (55.2% males). The number of pairs of parent and clinician assessments varied by assessment point (minimum = 104, maximum = 180). There was moderate or better agreement between raters (p < 0.05) at all assessment points for ambulation (ICC = 0.51-0.84) and pain (ICC = 0.39-0.84). Weak or better agreement (p < 0.05) was observed at all assessment points for vision (ICC = 0.23-0.79), and emotion (ICC = 0.22-0.69). Inter-rater agreement for HRQL ranged from weak to moderate (ICC = 0.31-0.50, p < 0.05). There was no significant agreement (p > 0.05) for dexterity at any assessment point (ICC = 0.05-0.16) and for cognition at Induction (ICC < 0.01). The mean difference (clinician minus parent) was clinically important for HRQL (difference = 0.07, p = 0.01) at Maintenance. CONCLUSIONS: Inter-rater agreement varies, from none to strong, by both type of utility score and assessment point. A clinically important mean difference in HRQL scores was observed. Parent and clinician reports should not be considered interchangeable. The results are consistent with studies of ALL patients assessed after completion of therapy. The five-year mortality rate for a population of adult brain tumor patients is typically high (≥50%). Tumor grade is a well-known predictor for mortality: low-grade (LG) tumors are associated with lower mortality rates than are high-grade (HG) tumors. METHODS: Prospective study of consecutive patients newly diagnosed with primary brain tumors attending a single regional centre. A cross-sectional survey collected baseline health status assessments for each patient after diagnosis, and in most cases surgery, but before radiotherapy or chemotherapy. Each participating patient completed a Health Utilities Index (HUI) Mark 2 (HUI2) and Mark 3 (HUI3) 15-item selfcomplete questionnaire, prior to encounter with assessing physician. The assessing physician, blind to patient's assessment, recorded a Karnofsky Performance Score (KPS) and a MiniMental Status Examination (MMSE) score. The life status for each patient was determined for the five-year period after assessment. Proportional hazards models estimated the IHOD for differences of: 0.10 in HUI utility scores; ten units in KPS; and five units in MMSE. Statistical significance was set at the 5% level.
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